# A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

> **NCT07064486** · PHASE3 · RECRUITING · sponsor: **BrightGene Bio-Medical Technology Co., Ltd.** · enrollment: 477 (estimated)

## Conditions studied

- Type 2 Diabetes (T2DM)

## Interventions

- **DRUG:** BGM0504
- **DRUG:** BGM0504
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT07064486
- **Lead sponsor:** BrightGene Bio-Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-04
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 477 (ESTIMATED)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064486, "A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07064486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*